AllAnalyst Report
logoArgusMarch 02, 2021

Catalent, Inc.: Reiterating BUY and raising target to $140

Current Price
Price Target
Earnings Estimate

Based in Somerset, New Jersey, Catalent has four operating segments: Softgel and Oral Technologies; Biologics; Oral and Specialty Delivery; and Clinical Supply Services. The company has facilities around the world.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.